Day2, July 6, 12:30 p.m., Session B:
The bavarian therapeutic strategy to combat the COVID 19 pandemic
Carsten Brockmeyer is the CEO of Formycon AG, Munich, one of the fastest growing Biotech-Pharma enterprises. Formycon focuses on treatments in ophthalmology, immunology and other key chronic diseases. Before joining Formycon, Carsten has held senior management positions at Baxter, Hexal, and Sandoz/Novartis. From 1998 to 2009, he was General Manager of Hexal Biotech GmbH. Carsten founded Brockmeyer Biopharma GmbH in 2010, a pharma and biotech consultancy, and helped to establish Formycon AG in 2012. Carsten holds a doctoral degree in human biology from Hannover Medical School and worked as postdoctoral fellow at the National Institutes of Health in Bethesda U.S.A., and the Institute of Immunology, LMU Munich, before entering the biopharma industry. His work in the field of biopharmaceuticals has been recognized with prestigious scientific awards.
Copyright © 2022 BioM Biotech Cluster Development GmbH
Alle Rechte vorbehalten